Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Operating expense | 8.4M | 3.5% |
| Net Income | -8M | 9.4% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 131M | 2.6% |
| Total Liabilities | 53M | 11.2% |
| Total Equity | 68M | 3.8% |
| Shares Outstanding | 18M | 64.1% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -12M | 119.7% |
| Cash from financing | 16M | 37.7% |
EPS
Financial Highlights for Citius Pharmaceuticals in Q3 '25
Operating Expenses for this period were 8.4M, showing a -3.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -8M, showing a 9.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
